{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T18:49:16Z","timestamp":1793558956712,"version":"4.5.0"},"reference-count":38,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.2967\/jnumed.120.255851","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T23:17:32Z","timestamp":1610147852000},"page":"1126-1132","source":"Crossref","is-referenced-by-count":29,"title":["Evaluation of Safety and Dosimetry of <sup>177<\/sup>Lu-DOTA-ZOL for Therapy of Bone Metastases"],"prefix":"10.2967","volume":"62","author":[{"given":"Ren\u00e9","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Eppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencke","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis David","family":"Jim\u00e9nez-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Soza-Ried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ribbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Meckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Zhernosekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasko","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"2021090907551053000_62.8.1126.1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.urology.2015.12.039","article-title":"Biology of bone metastases in prostate cancer","volume":"92","author":"Hensel","year":"2016","journal-title":"Urology."},{"key":"2021090907551053000_62.8.1126.2","doi-asserted-by":"crossref","first-page":"15024","DOI":"10.1038\/boneres.2015.24","article-title":"Contemporary approaches for imaging skeletal metastasis","volume":"3","author":"Ulmert","year":"2015","journal-title":"Bone Res."},{"key":"2021090907551053000_62.8.1126.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2006.07.030"},{"key":"2021090907551053000_62.8.1126.4","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"Ahmadzadehfar","year":"2016","journal-title":"Oncotarget."},{"key":"2021090907551053000_62.8.1126.5","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2007.374"},{"key":"2021090907551053000_62.8.1126.6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/ph10020045","article-title":"Novel radiolabeled bisphosphonates for PET diagnosis and endoradiotherapy of bone metastases","volume":"10","author":"Pfannkuchen","year":"2017","journal-title":"Pharmaceuticals (Basel)."},{"key":"2021090907551053000_62.8.1126.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2862-z"},{"key":"2021090907551053000_62.8.1126.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.155762"},{"key":"2021090907551053000_62.8.1126.9","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318279bf4d"},{"key":"2021090907551053000_62.8.1126.10","doi-asserted-by":"crossref","unstructured":"Meckel M Bergmann R Miederer M Roesch F. Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid. EJNMMI Radiopharm Chem. 2017;1:14.","DOI":"10.1186\/s41181-016-0017-1"},{"key":"2021090907551053000_62.8.1126.11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12149-015-0971-9","article-title":"Optimized production and quality control of 68Ga-EDTMP for small clinical trials","volume":"29","author":"Mirzaei","year":"2015","journal-title":"Ann Nucl Med."},{"key":"2021090907551053000_62.8.1126.12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/cbr.2014.1720","article-title":"Development of a 177LuBPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy","volume":"30","author":"Meckel","year":"2015","journal-title":"Cancer Biother Radiopharm."},{"key":"2021090907551053000_62.8.1126.13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/DHPS.S6285","article-title":"Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management","volume":"2","author":"Dalle Carbonare","year":"2010","journal-title":"Drug Healthc Patient Saf."},{"key":"2021090907551053000_62.8.1126.14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12149-019-01348-7","article-title":"Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET\/CT diagnosis of bone diseases","volume":"33","author":"Khawar","year":"2019","journal-title":"Ann Nucl Med."},{"key":"2021090907551053000_62.8.1126.15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13550-019-0566-x","article-title":"Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results","volume":"9","author":"Khawar","year":"2019","journal-title":"EJNMMI Res."},{"key":"2021090907551053000_62.8.1126.16","unstructured":"Chopra A. 68Ga-labeled (4-{(bis(phosphonomethyl))carbamoylmethyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid (BPAMD). Molecular Imaging and Contrast Agent Database (MICAD) website. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK114339\/. Created September 18, 2012. Updated November 21, 2012. Accessed July 19, 2021."},{"key":"2021090907551053000_62.8.1126.17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1874471011666180604083911","article-title":"In vivo evaluation of 225AcAc-DOTAZOL for \u03b1-therapy of bone metastases","volume":"11","author":"Pfannkuchen","year":"2018","journal-title":"Curr Radiopharm."},{"key":"2021090907551053000_62.8.1126.18","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med."},{"key":"2021090907551053000_62.8.1126.19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","article-title":"IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms","volume":"7","author":"Andersson","year":"2017","journal-title":"EJNMMI Res."},{"key":"2021090907551053000_62.8.1126.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1297-4"},{"key":"2021090907551053000_62.8.1126.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0146-6453(02)00021-0"},{"key":"2021090907551053000_62.8.1126.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1422-4"},{"key":"2021090907551053000_62.8.1126.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1072-6"},{"key":"2021090907551053000_62.8.1126.24","first-page":"34","article-title":"Radiolabelling of DOTAMZOL with 68Ga and 44Sc for clinical application","volume":"47","author":"Eppard","year":"2016","journal-title":"Endocr Abstr."},{"key":"2021090907551053000_62.8.1126.25","doi-asserted-by":"crossref","first-page":"20160748","DOI":"10.1259\/bjr.20160748","article-title":"Imaging and dosimetry for radium-223: the potential for personalized treatment","volume":"90","author":"Flux","year":"2017","journal-title":"Br J Radiol."},{"key":"2021090907551053000_62.8.1126.26","doi-asserted-by":"crossref","unstructured":"Rowland RE. Radium in humans: a review of U.S. studies; 1994.","DOI":"10.2172\/10114798"},{"key":"2021090907551053000_62.8.1126.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3125-3"},{"key":"2021090907551053000_62.8.1126.28","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0. National Cancer Institute website. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Published November 27, 2017. Accessed June 21, 2021."},{"key":"2021090907551053000_62.8.1126.29","doi-asserted-by":"publisher","DOI":"10.4103\/1450-1147.89780"},{"key":"2021090907551053000_62.8.1126.30","first-page":"492","article-title":"Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method","volume":"42","author":"Stabin","year":"2001","journal-title":"J Nucl Med."},{"key":"2021090907551053000_62.8.1126.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3174-7"},{"key":"2021090907551053000_62.8.1126.32","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2021090907551053000_62.8.1126.33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1148\/radiographics.9.2.2467331","article-title":"Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone","volume":"9","author":"Robinson","year":"1989","journal-title":"Radiographics."},{"key":"2021090907551053000_62.8.1126.34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fmed.2017.00046","article-title":"Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients\u2019 pain score analysis and personalized dosimetry","volume":"4","author":"Sharma","year":"2017","journal-title":"Front Med (Lausanne)."},{"key":"2021090907551053000_62.8.1126.35","first-page":"953","article-title":"Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases","volume":"44","author":"Liepe","year":"2003","journal-title":"J Nucl Med."},{"key":"2021090907551053000_62.8.1126.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3150-2"},{"key":"2021090907551053000_62.8.1126.37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/0146645318756253","article-title":"Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection","volume":"47","author":"Lassmann","year":"2018","journal-title":"Ann ICRP."},{"key":"2021090907551053000_62.8.1126.38","first-page":"80","article-title":"Radiopharmaceuticals for bone malignancy therapy","volume":"26","author":"Atkins","year":"1998","journal-title":"J Nucl Med Technol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.120.255851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T15:01:10Z","timestamp":1631199670000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.120.255851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,7,30]]},"published-print":{"date-parts":[[2021,8,1]]}},"alternative-id":["10.2967\/jnumed.120.255851"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.120.255851","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}